Hormonal changes induced by changing amounts of protein and phosphorus in the diet of healthy volunteers

Submission date	Recruitment status	Prospectively registered
06/05/2010	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
27/05/2010	Completed	Results
Last Edited	Condition category	Individual participant data
30/08/2011	Urological and Genital Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Marc Vervloet

Contact details

De Boelelaan 1117 Amsterdam Netherlands 1081 HV 31-20-4442673 m.vervloet@vumc.nl

Additional identifiers

Protocol serial number 2008/155

Study information

Scientific Title

Effects of changes in dietary phosphorus intake on fibroblast growth factor 23 (FGF23) levels in healthy volunteers: a controlled crossover trial

Study objectives

Background:

This study is related to patients with kidney disease. Kidney disease, as defined by a decline in estimated Glomerular Filtration Rate (GFR), as even in early stages related to disturbances in the metabolism of minerals, especially calcium and phosphorus, and Fibroblast growth factor 23 (FGF23). The latter is related to clinical endpoints and mortality.

Hypothesis

Changes in phosphate intake lead to parallel changes in levels of FGF23, even in healthy volunteers. These changes in FGF23 in turn lead to increases in phosphaturia and changes in levels of 1,25 dihydroxyvitamin D, both independent from possible changes in PTH or serum phosphate levels.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The local medical ethics committe (Medisch Ethische Toetsingscommissie) of Vrije University Medical Centre (VUMC) approved on the 11th of August 2008 (ref: 2008/155)

Study design

Non-randomised controlled crossover group trial

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Kidney disease

Interventions

Subjects are switched from regular diet to phosphate-restricted diet for two days, and the back to regular diet for ten days. After that they are switched from regular diet to phopsphate-enriched diet and the back again. No other interventions are made.

Both the primary and secondary endpoint were determined during the interventional periods, because changes induced by the intervention are almost immediate.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Changes in FGF23 levels, determined using sandwich ELISA for both C-terminal FGF23 (provided by Immutopics, San Clemente, USA) and Intact FGF23 (provided by Kainos, Japan).

Key secondary outcome(s))

- 1. Changes in phosphaturia
- 2. Changes in levels of metaboliotes of vitamin D (1,25 dihydroxyvitamin D) Outcomes analysed by standard laboratory techniques and radio-immuno assay (IDS, Tyne and Wear, UK) respectively

Completion date

31/12/2008

Eligibility

Key inclusion criteria

- 1. Male or female
- 2. Non-smoking subjects
- 3. Normal renal function, as defined by estimated Glomerular Filtration Rate (GFR) above 80 ml/min.
- 4. Females should have a negative test for pregnancy at baseline

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Αll

Key exclusion criteria

- 1. Abnormal kidney function
- 2. Substantial comorbidity

Date of first enrolment

01/08/2008

Date of final enrolment

31/12/2008

Locations

Countries of recruitment

Netherlands

Study participating centre

De Boelelaan 1117

Amsterdam Netherlands 1081 HV

Sponsor information

Organisation

Vrije University Medical Centre (VUMC) (Netherlands)

ROR

https://ror.org/00q6h8f30

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Vrije University Medical Centre (VUMC) (Netherlands) - Departments of nephrology and biochemistry

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet
Participant information sheet
11/11/2025 No Yes